Arresting Cancer Resistance

First-in-class dual PI3K/EGFR inhibitor with validated preclinical results, NCI partnership, and IND Approved

Nature Cancer Published | $15B+ Addressable Market | Mid-2026 Phase I Initiation
Overcomes Adaptive Resistance with Single Agent
IND Approved
View Clinical Progress Learn About MTX-531
Scroll to explore
Investment Opportunity

First-in-Class Oncology Asset Approaching Clinical Trials

$15B+ Addressable Market
Validated by Nature Cancer Publication
NCI NExT Partnership
IND Approved
Our Advantage

Why MTX-531 is Different

A single molecule solves the challenges of combination therapy

Two-Drug Combination
Challenges

  • Mismatched PK profiles – drugs peak at different times, reducing efficacy
  • Drug-drug interactions – unpredictable effects, complex dosing
  • Additive toxicities – overlapping side effects limit dosing
  • Complex development – two separate IND filings, separate trials
  • Patient compliance issues – multiple dosing schedules
VS

MTX-531 Single
Molecule Advantages

  • Coordinated PK profile – both targets inhibited simultaneously at optimal levels
  • No drug interactions – single agent eliminates exposure mismatch
  • Superior tolerability – PPARγ agonism reduces hyperglycemia toxicity
  • Streamlined development – single IND, faster path to patients
  • Simpler dosing – one pill, one schedule, better adherence

Result: Broader Therapeutic Window & Longer Patient Therapy

MTX-531's single-molecule approach enables sustained dual inhibition with reduced toxicity – exactly what's needed for durable responses in resistant cancers

Path to Market

Systematic advancement toward clinical validation

Preclinical 2022-2025
Nature Publication July 2024
IND-Enabling Studies Complete 2023-2025
IND Approved
Phase I Mid-2026
Partner With Us

We're seeking strategic partners to accelerate our mission of bringing this first-in-class therapy to patients.

View Development Progress
Confidential materials available under NDA
Get In Touch

Contact Us

Learn more about MEKanistic Therapeutics and MTX-531

General Information

General questions and information requests

info@mekanistic.com
Address

1015 Glenwood Ave
Minneapolis, MN 55405

Website

www.mekanistic.com